CD30, also known as tumor necrosis factor receptor superfamily member 8 (TNFRSF8), is a type I transmembrane glycoprotein encoded by TNFRSF8 in humans.1,2 Alternative splicing of the TNFRSF8 pre-mRNA produces one full-length isoform, CD30 long, and two short isoforms that contain truncated transmembrane and/or extracellular domains.1,3 CD30 exists as a monomer and is composed of an extracellular domain containing three cysteine-rich repeats (CRDs), a transmembrane domain, and a C-terminal cytoplasmic domain that facilitates intracellular signaling.2 It is expressed on certain subsets of activated T- or B cells, as well as in a variety of lymphoid neoplasms, including Hodgkin lymphoma and anaplastic large cell lymphomas (ALCLs).1 It can also exist in a soluble form, which is produced by proteolytic cleavage of CD30 at the cell surface and is found in the serum.1,2 CD30 is upregulated by mitogens, such as phorbol 12-myristate 13-acetate (TPA; Item No. 10008014), or viral stimulation, including Epstein-Barr virus (EBV) or HIV, as well as by the transcription factor JunB.1,3 Upon interaction with its ligand, TNFSF8/CD30L, which is also expressed on certain subsets of activated lymphocytes, CD30 assembles into a trimer that recruits TNF receptor-associated factor 1 (TRAF1), TRAF2, and TRAF5 to induce NF-κB- or ERK/MAPK-dependent downstream signaling, mediating a variety of cellular processes, including NF-κB activation, cell proliferation and survival, as well as apoptosis.1,2 Neutralization of CD30 with a monoclonal antibody reduces tumor growth in an ALCL patient-derived xenograft (PDX) mouse model.4 Serum levels of soluble CD30 (sCD30) are correlated with disease stage in patients with Hodgkin lymphoma or systemic lupus erythematosus (SLE).2 Cayman’s TNFRSF8/CD30 (C-Term) Rabbit Monoclonal Antibody (Clone RM425) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.WARNING This product is not for human or veterinary use.
